3413-27-2

Basic information

• Product Name: 4-PHENOXYPIPERIDINE HYDROCHLORIDE
• Synonyms: 4-PHENOXYPIPERIDINE HYDROCHLORIDE;4-PHENOXYPIPERIDINE HCL;Piperidine, 4-phenoxy-, hydrochloride;[(Piperidin-4-yl)oxy]benzene hydrochloride;4-Phenoxypiperidine hydrochloride≥ 97% (HPLC)
• CAS NO: 3413-27-2
• Molecular Formula: C11H16ClNO
• Molecular Weight: 213.7
• Mol File: 3413-27-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 182-184 °C
• Boiling Point: 278.3 °C at 760 mmHg
• Flash Point: 110.1 °C
• Appearance: /
• Density: 1.03 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-PHENOXYPIPERIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PHENOXYPIPERIDINE HYDROCHLORIDE(3413-27-2)
• EPA Substance Registry System: 4-PHENOXYPIPERIDINE HYDROCHLORIDE(3413-27-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 3413-27-2(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white powder

Upstream product

• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 108-95-2 phenol 

Relevant articles and documents

6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

AMINE DERIVATIVES

A compound of the formula: ???whereinX and X' are the same or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or an amino optionally having substituents, and at least one of X and X' represents a fluorine atom, a chlorine atom or an amino optionally having substituents;R1 and R2 represent a hydrogen atom or C1-6 alkyl optionally having substituents, or R1 and R2, together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring optionally having substituents;Y and Q are the same or different, and each represents a bond or a spacer having a main chain of 1 to 6 atoms;... represents a single bond or a double bond;T1 and T2 are the same or different, and each represents C(R9) (R9 represents a hydrogen atom, a hydroxy or C1-6 alkyl) or N, when each of the adjacent ... is a single bond, and C when the adjacent ... is a double bond; andAr represents an aromatic group optionally having substituents, a C3-9 cycloalkyl group optionally having substituents, a 3 to 9-membered saturated heterocyclic group optionally having substituents, a hydrogen atom or a halogen atom; provided that 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline; 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline and 1-benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide are excluded; a salt thereof or a prodrug thereof has an excellent somatostatin receptor binding inhibition action and is useful for preventing and/or treating diseases associated with somatostatin.